Euroopan unioni - englanti - EMA (European Medicines Agency)

immunomedics gmbh - sulesomab - osteomyelitis; radionuclide imaging - diagnostic agents - this medicinal product is for diagnostic use only.leukoscan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.leukoscan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - dutasteride, quantity: 500 microgram - capsule, soft - excipient ingredients: titanium dioxide; mono- and di- glycerides; lecithin; iron oxide yellow; butylated hydroxytoluene; medium chain triglycerides; gelatin; glycerol - avodart is indicated for use as monotherapy for the management of symptomatic benign prostatic hyperplasia (bph) or as combination therapy with an alpha blocker which is approved for use in bph and which has been dose titrated in accordance with the relevant recommendations in the product information for that alpha blocker.

Israel - englanti - Ministry of Health

glaxo smith kline (israel) ltd - dutasteride - capsules soft - dutasteride 0.5 mg - dutasteride - dutasteride - avodart is indicated for : treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph).reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.

Yhdysvallat - englanti - NLM (National Library of Medicine)

physicians total care, inc. - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride 0.5 mg - avodart® (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: - improve symptoms, - reduce the risk of acute urinary retention (aur), and - reduce the risk of the need for bph-related surgery. avodart in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. avodart is not approved for the prevention of prostate cancer. avodart is contraindicated for use in: - pregnancy. in animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. therefore, avodart may cause fetal harm when administered to a pregnant woman. if avodart is used during pregnancy or if the patient becomes pregnant while taking avodart, the patient should be apprised of the potential hazard to the fetus [see warnings and precautions (5.4), use in specific populations (8.1)] . - women of chil

Yhdysvallat - englanti - NLM (National Library of Medicine)

glaxosmithkline llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride 0.5 mg - avodart (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: avodart in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. avodart is not approved for the prevention of prostate cancer. avodart is contraindicated for use in: risk summary avodart is contraindicated for use in pregnancy because it may cause harm to the male fetus [see contraindications (4)] . avodart is not indicated for use in women. avodart is a 5 alpha‑reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of this conversion. these results are similar to observations in male infants with genetic 5 alpha‑reductase deficiency. in the u.s. general populat

Yhdysvallat - englanti - NLM (National Library of Medicine)

woodward pharma services llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - avodart (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: avodart in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. avodart is not approved for the prevention of prostate cancer. avodart is contraindicated for use in: risk summary avodart is contraindicated for use in pregnancy because it may cause harm to the male fetus [see contraindications (4)] . avodart is not indicated for use in women. avodart is a 5 alpha‑reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of this conversion. these results are similar to observations in male infants with genetic 5 alpha‑reductase deficiency. in the u.s. general populat

Uusi-Seelanti - englanti - Ministry for Primary Industries

schering-plough animal health limited - leptospira interrogans serovar hardjoprajitno; leptospira interrogans serovar pomona - leptospira interrogans serovar hardjoprajitno 0 vaccine; leptospira interrogans serovar pomona 0 vaccine - vaccine

Yhdysvallat - englanti - NLM (National Library of Medicine)

waylis therapeutics llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - avodart (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: avodart in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. avodart is not approved for the prevention of prostate cancer. avodart is contraindicated for use in: risk summary avodart is contraindicated for use in pregnancy because it may cause harm to the male fetus [see contraindications (4)] . avodart is not indicated for use in women. avodart is a 5 alpha‑reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of this conversion. these results are similar to observations in male infants with genetic 5 alpha‑reductase deficiency. in the u.s. general populat

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

ltt pharma limited - dutasteride - capsules, soft - 0.5 milligram

Australia - englanti - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - dutasteride -